TY - JOUR
T1 - Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
AU - Takahashi, Koichi
AU - Pemmaraju, Naveen
AU - Strati, Paolo
AU - Nogueras-Gonzalez, Graciela
AU - Ning, Jing
AU - Bueso-Ramos, Carlos
AU - Luthra, Rajyalakshmi
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Kantarjian, Hagop
AU - Garcia-Manero, Guillermo
PY - 2013/10/17
Y1 - 2013/10/17
N2 - We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t-CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t-CMML was significantly higher than that in the de novo CMML (P =.011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t-CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t-CMML be recognized as one of the therapy-related myeloid neoplasms.
AB - We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t-CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t-CMML was significantly higher than that in the de novo CMML (P =.011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t-CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t-CMML be recognized as one of the therapy-related myeloid neoplasms.
UR - http://www.scopus.com/inward/record.url?scp=84888259429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888259429&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-03-491399
DO - 10.1182/blood-2013-03-491399
M3 - Article
C2 - 23896412
AN - SCOPUS:84888259429
SN - 0006-4971
VL - 122
SP - 2807
EP - 2811
JO - Blood
JF - Blood
IS - 16
ER -